Global Psoriasis Biosimilars Market Size is valued at USD 8.5 billion in 2023 and is predicted to reach USD 19.3 billion by the year 2031 at a 10.9% CAGR during the forecast period for 2024 to 2031.
Psoriasis Biosimilars Market Size, Share & Trends Analysis Report By Drug Class (TNF-alpha inhibitors (Infliximab, Etanercept, Adalimumab), Other biosimilars), By Route of Administration (Subcutaneous, Intravenous, Oral, Topical), By Indication (Plaque psoriasis, Psoriatic arthritis, Other types), By Distribution Channel, By Region, And By Segment Forecasts, 2026 to 2035
Biosimilars for psoriasis are economically viable substitutes for original biologics employed in the management of moderate to severe psoriasis. These medications closely mimic the original biologics, such as Humira, Enbrel, and Remicade, targeting immunological pathways to diminish inflammation and manage symptoms. Biosimilars provide accessibility to effective psoriasis treatments and undergo stringent testing for safety and efficacy.
The increasing number of people affected by psoriasis globally and the need for more reasonably priced treatment alternatives are the main factors driving the psoriasis biosimilars market's expansion. The affordability of biosimilars is another important factor. A larger patient population may now afford therapy thanks to biosimilars, which provide an inexpensive substitute for biologic medications as healthcare systems throughout the globe struggle with growing treatment costs. Further encouraging acceptance and adoption is the increasing knowledge of patients and medical professionals regarding the effectiveness of biosimilars.
The psoriasis biosimilar market is segmented based on drug class, route of administration, indication, and distribution channel. Based on drug class, the market is segmented into TNF-alpha inhibitors (infliximab, etanercept, adalimumab) and other biosimilars. As per the route of administration, the market is segmented into subcutaneous, intravenous. By indication, the market is segmented into plaque psoriasis, psoriatic arthritis, and other types. The distribution channel segment is categorised into hospital pharmacies, retail pharmacy chains and online pharmacies.
The plaque psoriasis category is expected to hold a major global market share. The need for effective and reasonably priced treatments has arisen from the chronic nature of plaque psoriasis and its detrimental effects on quality of life. Targeting particular pathways of the inflammatory process, biologics have shown promise in the treatment of moderate to severe plaque psoriasis. Yet, many patients are unable to afford the expensive therapies made from original biological processes, which presents a great opportunity for biosimilars. Biosimilars are very desirable to patients and healthcare professionals alike because they have profiles of efficacy and safety that are comparable to those of reference biologics but at significantly lower costs.
Retail pharmacies are typically found in very big businesses that span several cities or rural areas. This eliminates the need for the psoriasis sufferer to drive a great distance in order to obtain their biosimilar medication, which would be problematic for most of them as they depend on their meds frequently. Extended hours and easily accessible places are examples of convenience factors. Better prescription management results from this, and walk-in services are advantageous when managing a chronic ailment such as psoriasis, which frequently necessitates ongoing care.
The North American psoriasis biosimilar market is expected to capture a significant part of market revenue. North America possesses a formidable infrastructure for biotechnology research and development due to its vigorous pharmaceutical innovation. Moreover, the Asia Pacific region exhibited a significant market share. Contemporary technologies are employed in the advancement of biosimilars due to the region's significance in the biopharmaceutical sector. The prevalence in the population underscores the necessity for effective treatment, with biosimilars assuming a notably important role in the control of severe diseases.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 8.5 Bn |
| Revenue Forecast In 2031 | USD 19.3 Bn |
| Growth Rate CAGR | CAGR of 10.9% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Class, Route Of Administration, Indication, And Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Alvotech, Amgen, Amgen Inc., Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), Stada Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, Other prominent players. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.